|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2010-4-16
|
|
pubmed:abstractText |
A phase I study was conducted to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of R1507-a fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor. Experimental design: Patients with advanced solid tumors were assigned to receive i.v. R1507 weekly (qW), starting with 1 mg/kg. Subsequent cohorts were dosed at 3 and then 9 mg/kg. An additional 12 patients received 9 mg/kg R1507 qW. Patients remained on the study until the development of a dose-limiting toxicity or progressive disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AisnerJosephJ,
pubmed-author:BenjaminRobertR,
pubmed-author:EckhardtS GailSG,
pubmed-author:EidJoseph EJE,
pubmed-author:GoreLiaL,
pubmed-author:GreigGerardG,
pubmed-author:HabbenKaiK,
pubmed-author:KurzrockRazelleR,
pubmed-author:LeongStephenS,
pubmed-author:McCarthyCinara DCD,
pubmed-author:PatnaikAmitaA,
pubmed-author:WarrenTerriT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2458-65
|
|
pubmed:dateRevised |
2011-8-2
|
|
pubmed:meshHeading |
pubmed-meshheading:20371689-Administration, Oral,
pubmed-meshheading:20371689-Adolescent,
pubmed-meshheading:20371689-Adult,
pubmed-meshheading:20371689-Aged,
pubmed-meshheading:20371689-Antibodies, Monoclonal,
pubmed-meshheading:20371689-Female,
pubmed-meshheading:20371689-Humans,
pubmed-meshheading:20371689-Male,
pubmed-meshheading:20371689-Maximum Tolerated Dose,
pubmed-meshheading:20371689-Middle Aged,
pubmed-meshheading:20371689-Neoplasms,
pubmed-meshheading:20371689-Receptor, IGF Type 1,
pubmed-meshheading:20371689-Survival Rate,
pubmed-meshheading:20371689-Tissue Distribution,
pubmed-meshheading:20371689-Treatment Outcome,
pubmed-meshheading:20371689-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030, USA. rkurzroc@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
